{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:37:54Z","timestamp":1793241474963,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose\u2013concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20\u201360\u00a0ng\/ml) is applicable for minors. In the 64 patients (aged 11\u201318\u00a0years) included, a positive correlation between daily dose and the active moiety (RIS\n                    <jats:sub>am<\/jats:sub>\n                    ) concentration was found (\n                    <jats:italic>r<\/jats:italic>\n                    <jats:sub>s<\/jats:sub>\n                    \u2009=\u20090.49,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001) with variation in dose explaining 24% (\n                    <jats:italic>r<\/jats:italic>\n                    <jats:sub>s<\/jats:sub>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.240) of the variability in serum concentrations. While the RIS\n                    <jats:sub>am<\/jats:sub>\n                    concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RISam\u00a0concentrations than patients without (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.05). Considering EPS, the upper threshold of the therapeutic range of RIS\n                    <jats:sub>am<\/jats:sub>\n                    was determined to be 33\u00a0ng\/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.\n                  <\/jats:p>","DOI":"10.1007\/s00702-022-02485-6","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T05:02:33Z","timestamp":1647579753000},"page":"689-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone"],"prefix":"10.1007","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-1424","authenticated-orcid":false,"given":"R.","family":"Taurines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1925-6228","authenticated-orcid":false,"given":"S.","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Preuss-Wiedenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wewetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4333-1494","authenticated-orcid":false,"given":"P.","family":"Plener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-8299","authenticated-orcid":false,"given":"M.","family":"Romanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-0954","authenticated-orcid":false,"given":"K. M.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"2485_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1089\/cap.2006.0045","volume":"17","author":"W Aichhorn","year":"2007","unstructured":"Aichhorn W, Marksteiner J, Walch T, Zernig G, Hinterhuber H, Stuppaeck C, Kemmler G (2007a) Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol 17:665\u2013674","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2485_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00115-006-2112-0","volume":"78","author":"W Aichhorn","year":"2007","unstructured":"Aichhorn W, Whitworth AB, Weiss EM, Hinterhuber H, Marksteiner J (2007b) Differences between men and women in side effects of second-generation antipsychotics. Nervenarzt 78:45\u201352","journal-title":"Nervenarzt"},{"key":"2485_CR3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.clinthera.2007.07.026","volume":"29","author":"MG Aman","year":"2007","unstructured":"Aman MG, Vinks AA, Remmerie B, Mannaert E, Ramadan Y, Masty J, Lindsay RL, Malone K (2007) Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 29:1476\u20131486","journal-title":"Clin Ther"},{"key":"2485_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/00007691-200312000-00003","volume":"25","author":"M Aravagiri","year":"2003","unstructured":"Aravagiri M, Marder SR, Nuechterlein KH, Gitlin MJ (2003) Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit 25:657\u2013664","journal-title":"Ther Drug Monit"},{"key":"2485_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-2007-979308","volume":"31","author":"M Aravagiri","year":"1998","unstructured":"Aravagiri M, Marder SR, Wirshing D, Wirshing WC (1998) Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 31:102\u2013109","journal-title":"Pharmacopsychiatry"},{"key":"2485_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00787-005-0515-2","volume":"15","author":"JL Armenteros","year":"2006","unstructured":"Armenteros JL, Davies M (2006) Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis. Eur Child Adolesc Psychiatry 15:141\u2013148","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2485_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1055\/s-2002-36389","volume":"35","author":"R Berecz","year":"2002","unstructured":"Berecz R, LLerena A, de la Rubia A, Gomez J, Kellermann M, Dorado P, Degrell I (2002) Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 35:231\u2013234","journal-title":"Pharmacopsychiatry"},{"key":"2485_CR8","first-page":"193","volume":"30","author":"RL Borison","year":"1994","unstructured":"Borison RL, Diamond B, Pathiraja A, Meibach RC (1994) Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull 30:193\u2013197","journal-title":"Psychopharmacol Bull"},{"key":"2485_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/FTD.0b013e3182577c43","volume":"34","author":"SV Bowskill","year":"2012","unstructured":"Bowskill SV, Handley SA, Fisher DS, Flanagan RJ, Patel MX (2012) Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002\u20132010. Ther Drug Monit 34:349\u2013355","journal-title":"Ther Drug Monit"},{"key":"2485_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/cap.2010.0038","volume":"21","author":"CA Calarge","year":"2011","unstructured":"Calarge CA, del Miller D (2011) Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol 21:163\u2013169","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2485_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/acps.12794","volume":"136","author":"I Castberg","year":"2017","unstructured":"Castberg I, Westin AA, Skogvoll E, Spigset O (2017) Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand 136:455\u2013464","journal-title":"Acta Psychiatr Scand"},{"key":"2485_CR12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1021\/acschemneuro.8b00159","volume":"9","author":"TC Chopko","year":"2018","unstructured":"Chopko TC, Lindsley CW (2018) Classics in chemical neuroscience: risperidone. ACS Chem Neurosci 9:1520\u20131529","journal-title":"ACS Chem Neurosci"},{"key":"2485_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.psc.2012.06.007","volume":"35","author":"CU Correll","year":"2012","unstructured":"Correll CU, Gallego JA (2012) Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am 35:661\u2013681","journal-title":"Psychiatr Clin North Am"},{"key":"2485_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1089\/cap.2005.15.68","volume":"15","author":"S dosReis","year":"2005","unstructured":"dosReis S, Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL (2005) Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol 15:68\u201377","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2485_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.psyneuen.2007.10.010","volume":"33","author":"F Duval","year":"2008","unstructured":"Duval F, Guillon MS, Mokrani MC, Crocq MA, Garcia Duarte F (2008) Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder. Psychoneuroendocrinology 33:255\u2013259","journal-title":"Psychoneuroendocrinology"},{"key":"2485_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1055\/s-0031-1286291","volume":"44","author":"KM Egberts","year":"2011","unstructured":"Egberts KM, Mehler-Wex C, Gerlach M (2011) Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 44:249\u2013253","journal-title":"Pharmacopsychiatry"},{"key":"2485_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1024\/1422-4917\/a000329","volume":"43","author":"K Egberts","year":"2015","unstructured":"Egberts K, Karwautz A, Plener PL, Mehler-Wex C, K\u00f6lch M, Dang SY, Taurines R, Romanos M, Gerlach M (2015) Pharmacovigilance in child and adolescent psychiatry. Z Kinder Jugendpsychiatr Psychother 43:21\u201328","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"2485_CR18","doi-asserted-by":"publisher","unstructured":"Egberts KM, Gelach M, Correll C, Plener PL, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleichhaker C, H\u00e4ge A, Hellenschmidt T, Imgart H, Kaess M, Karwautz A, K\u00f6lch M, Reitzle K, Renner T, Reuter-Dang S-Y, Rexroth C, Schulte-K\u00f6rne G, Theisen F, Walitza S, Wewetzer C, Fekete S, Taurines R, Romanos M (2022) Serious adverse drug reactions in children and adolescents treated on- and off-label with antidepressants and antipsychotics in clinical practice. Pharmacopsychiatry. https:\/\/doi.org\/10.1055\/a-1716-1856","DOI":"10.1055\/a-1716-1856"},{"key":"2485_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1055\/a-1302-8108","volume":"54","author":"S Fekete","year":"2021","unstructured":"Fekete S, Scherf-Clavel M, Gerlach M, Romanos M, Kittel-Schneider S, Unterecker S, Egberts K (2021) Dose-corrected serum concentrations and metabolite to parent compound ratios of venlafaxine and risperidone from childhood to old age. Pharmacopsychiatry 54:117\u2013125","journal-title":"Pharmacopsychiatry"},{"key":"2485_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jaac.2016.03.014","volume":"55","author":"KD Gadow","year":"2016","unstructured":"Gadow KD, Brown NV, Arnold LE, Buchan-Page KA, Bukstein OG, Butter E, Farmer CA, Findling RL, Kolko DJ, Molina BS, Rice RR Jr, Schneider J, Aman MG (2016) Severely aggressive children receiving stimulant medication versus stimulant and risperidone: 12-month follow-up of the TOSCA Trial. J Am Acad Child Adolesc Psychiatry 55:469\u2013478","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2485_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/104454604773840472","volume":"14","author":"A Gagliano","year":"2004","unstructured":"Gagliano A, Germano E, Pustorino G, Impallomeni C, D\u2019Arrigo C, Calamoneri F, Spina E (2004) Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39\u201347","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2485_CR22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10578-013-0427-1","volume":"45","author":"A Ghanizadeh","year":"2014","unstructured":"Ghanizadeh A, Haghighi A (2014) Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev 45:596\u2013603","journal-title":"Child Psychiatry Hum Dev"},{"key":"2485_CR23","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication, Rockville"},{"key":"2485_CR24","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","volume":"27","author":"O Halfdanarson","year":"2017","unstructured":"Halfdanarson O, Zoega H, Aagaard L, Bernardo M, Brandt L, Fuste AC, Furu K, Garuoliene K, Hoffmann F, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, Litchfield M, Lopez SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Pearson SA, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Skurtveit S, Verdoux H, Wang LJ, Yahni CZ, Bachmann CJ (2017) International trends in antipsychotic use: A study in 16 countries, 2005\u20132014. Eur Neuropsychopharmacol 27:1064\u20131076","journal-title":"Eur Neuropsychopharmacol"},{"key":"2485_CR25","doi-asserted-by":"publisher","first-page":"102744","DOI":"10.1016\/j.ajp.2021.102744","volume":"63","author":"N Hashimoto","year":"2021","unstructured":"Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Numata S, Hori H, Iida H, Ichihashi K, Furihata R, Murata A, Tsuboi T, Takeshima M, Kyou Y, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Hishimoto A, Miura K, Matsumoto J, Ohi K, Yamada H, Inada K, Watanabe K, Shimoda K, Hashimoto R (2021) Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Asian J Psychiatr 63:102744","journal-title":"Asian J Psychiatr"},{"key":"2485_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00004850-199503000-00003","volume":"10","author":"H He","year":"1995","unstructured":"He H, Richardson JS (1995) A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 10:19\u201330","journal-title":"Int Clin Psychopharmacol"},{"key":"2485_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/FTD.0000000000000018","volume":"36","author":"M Hendset","year":"2014","unstructured":"Hendset M, Molden E, Knape M, Hermann M (2014) Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther Drug Monit 36:80\u201385","journal-title":"Ther Drug Monit"},{"issue":"Suppl","key":"2485_CR28","first-page":"13","volume":"55","author":"J Heykants","year":"1994","unstructured":"Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55(Suppl):13\u201317","journal-title":"J Clin Psychiatry"},{"key":"2485_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","volume":"41","author":"C Hiemke","year":"2019","unstructured":"Hiemke C (2019) Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. Ther Drug Monit 41:174\u2013179","journal-title":"Ther Drug Monit"},{"key":"2485_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51:9\u201362","journal-title":"Pharmacopsychiatry"},{"key":"2485_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00213-006-0537-6","volume":"191","author":"J Ipser","year":"2007","unstructured":"Ipser J, Stein DJ (2007) Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents. Psychopharmacology 191:127\u2013140","journal-title":"Psychopharmacology"},{"key":"2485_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1089\/cap.2005.15.318","volume":"15","author":"BN Kim","year":"2005","unstructured":"Kim BN, Lee CB, Hwang JW, Shin MS, Cho SC (2005) Effectiveness and safety of risperidone for children and adolescents with chronic tic or Tourette disorders in Korea. J Child Adolesc Psychopharmacol 15:318\u2013324","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2485_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1055\/s-0029-1239540","volume":"43","author":"K Klampfl","year":"2010","unstructured":"Klampfl K, Taurines R, Preuss A, Burger R, Rothenhofer S, Wewetzer C, Pfuhlmann B, Fegert J, Gerlach M, Mehler-Wex C (2010) Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 43:58\u201365","journal-title":"Pharmacopsychiatry"},{"key":"2485_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bcp.14465","volume":"87","author":"SM Kloosterboer","year":"2021","unstructured":"Kloosterboer SM, de Winter BCM, Reichart CG, Kouijzer MEJ, de Kroon MMJ, van Daalen E, Ester WA, Rieken R, Dieleman GC, van Altena D, Bartelds B, van Schaik RHN, Nasserinejad K, Hillegers MHJ, van Gelder T, Dierckx B, Koch BCP (2021) Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Br J Clin Pharmacol 87:1069\u20131081","journal-title":"Br J Clin Pharmacol"},{"key":"2485_CR35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/14740338.2020.1770224","volume":"19","author":"SM Kloosterboer","year":"2020","unstructured":"Kloosterboer SM, Vierhout D, Stojanova J, Egberts KM, Gerlach M, Dieleman GC, Hillegers MHJ, Passe KM, Gelder TV, Dierckx B, Koch BCP (2020) Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review. Expert Opin Drug Saf 19:873\u2013890","journal-title":"Expert Opin Drug Saf"},{"key":"2485_CR36","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1089\/cap.2018.0037","volume":"28","author":"ES Lee","year":"2018","unstructured":"Lee ES, Vidal C, Findling RL (2018) A focused review on the treatment of pediatric patients with atypical antipsychotics. J Child Adolesc Psychopharmacol 28:582\u2013605","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2485_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","volume":"30","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N, Steinwachs DM (2004) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 30:193\u2013217","journal-title":"Schizophr Bull"},{"key":"2485_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-2007-973836","volume":"40","author":"J Leon","year":"2007","unstructured":"Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ (2007) A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40:93\u2013102","journal-title":"Pharmacopsychiatry"},{"key":"2485_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P et al (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1\u2013100","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2485_CR40","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jpeds.2018.12.033","volume":"208","author":"XI Liu","year":"2019","unstructured":"Liu XI, Schuette P, Burckart GJ, Green DJ, La J, Burnham JM, Rakhmanina N, Robb A, Huang SM, van den Anker JN (2019) A comparison of Pediatric and Adult Safety Studies for Antipsychotic and Antidepressant Drugs submitted to the United States Food and Drug Administration. J Pediatr 208:236\u2013242","journal-title":"J Pediatr"},{"key":"2485_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ejps.2010.06.016","volume":"41","author":"I Locatelli","year":"2010","unstructured":"Locatelli I, Kastelic M, Koprivsek J, Kores-Plesnicar B, Mrhar A, Dolzan V, Grabnar I (2010) A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur J Pharm Sci 41:289\u2013298","journal-title":"Eur J Pharm Sci"},{"key":"2485_CR42","first-page":"1134","volume":"21","author":"G Mannens","year":"1993","unstructured":"Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21:1134\u20131141","journal-title":"Drug Metab Dispos"},{"key":"2485_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1753-2000-3-14","volume":"3","author":"C Mehler-Wex","year":"2009","unstructured":"Mehler-Wex C, Kolch M, Kirchheiner J, Antony G, Fegert JM, Gerlach M (2009) Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health 3:14","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"2485_CR44","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.pnpbp.2009.08.009","volume":"33","author":"G Migliardi","year":"2009","unstructured":"Migliardi G, Spina E, D\u2019Arrigo C, Gagliano A, Germano E, Siracusano R, Diaz FJ, de Leon J (2009) Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry 33:1496\u20131501","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2485_CR45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.4088\/JCP.v65n0408","volume":"65","author":"A Miller","year":"2004","unstructured":"Miller A, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B (2004) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 65:500\u2013508","journal-title":"J Clin Psychiatry"},{"key":"2485_CR46","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00228-010-0812-7","volume":"66","author":"Y Nazirizadeh","year":"2010","unstructured":"Nazirizadeh Y, Vogel F, Bader W, Haen E, Pfuhlmann B, Grunder G, Paulzen M, Schwarz M, Zernig G, Hiemke C (2010) Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 66:797\u2013803","journal-title":"Eur J Clin Pharmacol"},{"key":"2485_CR47","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bcpt.12570","volume":"119","author":"N Ngamsamut","year":"2016","unstructured":"Ngamsamut N, Hongkaew Y, Vanwong N, Srisawasdi P, Puangpetch A, Chamkrachangpada B, Tan-Khum T, Limsila P, Sukasem C (2016) 9-Hydroxyrisperidone-induced hyperprolactinaemia in Thai children and adolescents with autism spectrum disorder. Basic Clin Pharmacol Toxicol 119:267\u2013272","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2485_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.psyneuen.2016.07.009","volume":"73","author":"M Paulzen","year":"2016","unstructured":"Paulzen M, Haen E, Stegmann B, Hiemke C, Grunder G, Lammertz SE, Schoretsanitis G (2016) Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. Psychoneuroendocrinology 73:9\u201315","journal-title":"Psychoneuroendocrinology"},{"key":"2485_CR49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00228-015-1982-0","volume":"72","author":"M Pozzi","year":"2016","unstructured":"Pozzi M, Cattaneo D, Baldelli S, Fucile S, Capuano A, Bravaccio C, Sportiello L, Bertella S, Auricchio F, Bernardini R, Ferrajolo C, Guastella G, Mani E, Carnovale C, Pisano S, Rafaniello C, Riccio MP, Rizzo R, Scuderi MG, Sperandeo S, Villa L, Pascotto A, Molteni M, Rossi F, Radice S, Clementi E (2016) Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Eur J Clin Pharmacol 72:285\u2013293","journal-title":"Eur J Clin Pharmacol"},{"key":"2485_CR50","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","volume":"255","author":"M Riedel","year":"2005","unstructured":"Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N, Moller HJ (2005) Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255:261\u2013268","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2485_CR51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/cap.2011.0109","volume":"22","author":"Y Roke","year":"2012","unstructured":"Roke Y, Buitelaar JK, Boot AM, Tenback D, van Harten PN (2012) Risk of hyperprolactinemia and sexual side effects in males 10\u201320 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 22:432\u2013439","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2485_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00004583-198905000-00017","volume":"28","author":"AT Russell","year":"1989","unstructured":"Russell AT, Bott L, Sammons C (1989) The phenomenology of schizophrenia occurring in childhood. J Am Acad Child Adolesc Psychiatry 28:399\u2013407","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2485_CR53","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/01.jcp.0000130558.86125.5b","volume":"24","author":"DJ Safer","year":"2004","unstructured":"Safer DJ (2004) A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429\u2013436","journal-title":"J Clin Psychopharmacol"},{"key":"2485_CR54","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1176\/appi.ajp.160.3.438","volume":"160","author":"DJ Safer","year":"2003","unstructured":"Safer DJ, Zito JM, DosReis S (2003) Concomitant psychotropic medication for youths. Am J Psychiatry 160:438\u2013449","journal-title":"Am J Psychiatry"},{"key":"2485_CR55","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/JCP.0000000000000601","volume":"36","author":"G Schoretsanitis","year":"2016","unstructured":"Schoretsanitis G, Haen E, Grunder G, Stegmann B, Schruers KR, Hiemke C, Lammertz SE, Paulzen M (2016) Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under combined treatment. J Clin Psychopharmacol 36:554\u2013561","journal-title":"J Clin Psychopharmacol"},{"key":"2485_CR56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.schres.2016.12.016","volume":"185","author":"G Schoretsanitis","year":"2017","unstructured":"Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Grunder G, Paulzen M (2017) Effect of smoking on risperidone pharmacokinetics - a multifactorial approach to better predict the influence on drug metabolism. Schizophr Res 185:51\u201357","journal-title":"Schizophr Res"},{"key":"2485_CR57","first-page":"19cs13169","volume":"19","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Gr\u00fcnder G, American Society of Clinical Psychopharmacology, Pharmakopsychiatrie (2020) Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry 19:19cs13169","journal-title":"J Clin Psychiatry"},{"key":"2485_CR58","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","volume":"19","author":"M Solmi","year":"2020","unstructured":"Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU (2020) Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry 19:214\u2013232","journal-title":"World Psychiatry"},{"key":"2485_CR59","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s002130000576","volume":"153","author":"E Spina","year":"2001","unstructured":"Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153:238\u2013243","journal-title":"Psychopharmacology"},{"key":"2485_CR60","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/11531730-000000000-00000","volume":"49","author":"A Thyssen","year":"2010","unstructured":"Thyssen A, Vermeulen A, Fuseau E, Fabre MA, Mannaert E (2010) Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet 49:465\u2013478","journal-title":"Clin Pharmacokinet"},{"key":"2485_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","volume":"27","author":"PW Troost","year":"2007","unstructured":"Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ (2007) Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 27:52\u201357","journal-title":"J Clin Psychopharmacol"},{"key":"2485_CR62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF02245444","volume":"114","author":"LE van Beijsterveldt","year":"1994","unstructured":"van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, Heykants JJ (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 114:53\u201362","journal-title":"Psychopharmacology"},{"key":"2485_CR63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1024\/1422-4917\/a000632","volume":"47","author":"TD Vloet","year":"2019","unstructured":"Vloet TD, Egberts K, Taurines R, Wewetzer C, Mehler-Wex C, Plener PL, Romanos M, Gerlach M (2019) Polypharmacy of psychotropic drugs in child and adolescent psychiatry in Germany - rather the rule than the exception. Z Kinder Jugendpsychiatr Psychother 47:193\u2013202","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"2485_CR64","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF (2009a) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689\u2013723","journal-title":"Clin Pharmacokinet"},{"key":"2485_CR65","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF (2009b) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48:761\u2013804","journal-title":"Clin Pharmacokinet"},{"key":"2485_CR66","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1745-7254.2006.00256.x","volume":"27","author":"ZL Zhou","year":"2006","unstructured":"Zhou ZL, Li X, Peng HY, Yu XY, Yang M, Su FL, Wang F, Zhu RH, Deng CY, Lin QX, Wang CY, Li WB, Lin SG, Li HD (2006) Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin 27:381\u2013386","journal-title":"Acta Pharmacol Sin"},{"key":"2485_CR67","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1542\/peds.2007-0212","volume":"121","author":"JM Zito","year":"2008","unstructured":"Zito JM, Safer DJ, Sai D, Gardner JF, Thomas D, Coombes P, Dubowski M, Mendez-Lewis M (2008) Psychotropic medication patterns among youth in foster care. Pediatrics 121:e157-163","journal-title":"Pediatrics"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02485-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-022-02485-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02485-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T10:05:55Z","timestamp":1654941955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-022-02485-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":67,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2485"],"URL":"https:\/\/doi.org\/10.1007\/s00702-022-02485-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"2 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}